ReviewInvestigative radiology2018
Methodological Aspects for Preclinical Evaluation of Gadolinium Presence in Brain Tissue: Critical Appraisal and Suggestions for Harmonization-A Joint Initiative.
Review in Investigative radiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 49 citations in OpenAlex.
- Gadolinium Contrast Agent Deposition in Children.Journal of magnetic resonance imaging : JMRI · 2025Review
- The safety of magnetic resonance imaging contrast agents.Frontiers in toxicology · 2024Article
- Ten years of gadolinium retention and deposition: ESMRMB-GREC looks backward and forward.European radiology · 2024Review
- Intracerebral gadolinium deposition following blood-brain barrier disturbance in two different mouse models.Scientific reports · 2023Article
- Gadolinium Deposition in the Rat Brain Measured with Quantitative MRI versus Elemental Mass Spectrometry.Radiology · 2023Article
- Gadolinium in Medical Imaging-Usefulness, Toxic Reactions and Possible Countermeasures-A Review.Biomolecules · 2022Review
- Gadolinium retention: should pediatric radiologists be concerned, and how to frame conversations with families.Pediatric radiology · 2022Review
- Comparison of linear versus macrocyclic gadolinium chelates in rat skeletal muscle.Northern clinics of Istanbul · 2022Article
- Gadolinium Clearance in the First 5 Weeks After Repeated Intravenous Administration of Gadoteridol, Gadoterate Meglumine, and Gadobutrol to rats.Journal of magnetic resonance imaging : JMRI · 2021Article
- Contrast-Free Detection of Focused Ultrasound-Induced Blood-Brain Barrier Opening Using Diffusion Tensor Imaging.IEEE transactions on bio-medical engineering · 2021Article
- Gadolinium retention within multiple rat organs after intra-articular administration of gadolinium-based contrast agents.Skeletal radiology · 2021Article
- Overlapping roles of NADPH oxidase 4 for diabetic and gadolinium-based contrast agent-induced systemic fibrosis.American journal of physiology. Renal physiology · 2021Article
- Molecular MR Imaging of Prostate Cancer.Biomedicines · 2020Review
- New prostate MRI techniques and sequences.Abdominal radiology (New York) · 2020Review
- Long-Term Evaluation of Gadolinium Retention in Rat Brain After Single Injection of a Clinically Relevant Dose of Gadolinium-Based Contrast Agents.Investigative radiology · 2020Article
- Macrocyclic MR contrast agents: evaluation of multiple-organ gadolinium retention in healthy rats.Insights into imaging · 2020Article
- Article
- Yttrium-86 Is a Positron Emitting Surrogate of Gadolinium for Noninvasive Quantification of Whole-Body Distribution of Gadolinium-Based Contrast Agents.Angewandte Chemie (International ed. in English) · 2020Article
- Gadolinium Retention as a Safety Signal: Experience of a Manufacturer.Investigative radiology · 2020Review
- Standardized assessment of the signal intensity increase on unenhanced T1-weighted images in the brain: the European Gadolinium Retention Evaluation Consortium (GREC) Task Force position statement.European radiology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gadolinium (Gd)-based contrast agents (GBCAs) are pharmaceuticals that have been approved for 30 years and used daily in millions of patients worldwide. Their clinical benefits are indisputable. Recently, unexpected long-term presence of Gd in the brain has been reported by numerous retrospective clinical studies and confirmed in preclinical models particularly after linear GBCA (L-GBCA) compared with macrocyclic GBCA (M-GBCA). Even if no clinical consequences of Gd presence in brain tissue has been demonstrated so far, in-depth investigations on potential toxicological consequences and the fate of Gd in the body remain crucial to potentially adapt the clinical use of GBCAs, as done during the nephrogenic systemic fibrosis crisis. Preclinical models are instrumental in the understanding of the mechanism of action as well as the potential safety consequences. However, such models may be associated with risks of biases, often related to the protocol design. Selection of adequate terminology is also crucial. This review of the literature intends to summarize and critically discuss the main methodological aspects for accurate design and translational character of preclinical studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.